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Abstract 
Epilepsy is a chronic nervous disorder caused by abnormal electrical 
signals in the brain. Epileptic seizures can be minimized with the use of 
anticonvulsant drugs. Use of anticonvulsants by a pregnant woman poses 
the risk of damage to an unborn baby. One of the most common 
anticonvulsants is diphenylhydantoin (DPH). 
To study the effects on the fetus of preimplantation exposure to 
anticonvulsants, DPH was injected into AI J and NSA strains of mice 
r ": 
during the first five days of pregnancy. Fetuses were examined externally 
on Day 1 8 of development and later dissected for internal examination. 
The DPH mice of both strains showed no internal or external anomalies 
other than reduced size. Other effects found were the inability to 
establish pregnancy, increases in resorptions, and smaller litter size. 
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Introduction 
In order to understand the effects on the fetus of diphenylhydantoin 
injected during preimplantation into mice, it is necessary to understand 
background information. Therefore, information will first be given on 
epilepsy, the risks of anticonvulsant use, factors involved in expression of 
anomalies, and the teratogenicity of diphenylhydantoin. 
Epilepsy 
Epilepsy is a chronic nervous disorder associated with abnormal 
electrical activity in the brain (Encyclopedia Americana 1993). The known 
causes of epilepsy are inherited diseases, inherited tendency for epilepsy, 
fetal exposure to drugs, head injuries, brain tumors, and blood clots in the 
brain (Gumnit 1990). According to Gumnit (1990), about 2% of the general 
population develops epilepsy by age 40. According to another source 
(Finnell 1981), 0.3-0.5% of the population consists of epileptic women. 
There are two types of epilepsy, namely, generalized and partial (Sands 
and Minters 1977). Generalized epilepsy is when seizures involve the 
whole brain. Partial epilepsy is when seizures involve or begin in one area 
of the brain. In a French study, researchers classified 6,000 private 
epilepsy patients. One quarter could not be classified but of the remaining 
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patients, 37.7% had generalized epilepsy and 62.3% had partial epilepsy 
(Gastaut et al. 1 975). Epileptic seizures can be minimized with the use of 
anticonvulsant drugs. 
Risks of Anticonvulsant Drug Use 
There are over 20 anticonvulsant drugs, including; diphenylhydantoin 
(DPH or more commonly Dilantin or phenytoin), carbamazepine, 
phenobarbital, valproic acid, trimethadione (Tridione), primidone, 
phensuximide (Milontin), among others. DPH, valproic acid, Tridione, 
carbamazepine, and combinations of these pose the greatest risk for 
congenital malformations in humans (Finnell et a1. 1992). Congenital 
malformations are a result of the ability of anticonvulsant drugs to pass 
through the placenta to the embryo (Speidel and Meadow 1972, Melchior et 
al. 1967, Mirkin 1971). Use of anticonvulsants increases the frequency of 
occurrence of congenital malformations two to three-fold (Speidel and 
Meadow 1972, Lowe 1973). One in 400 women use anticonvulsants and 
2/3 of women that use anticonvulsants, use DPH either alone or in 
combination with other anticonvulsants (Biale et al. 1975). DPH has been 
shown to cause congenital malformations in mice (Massey 1966, Gibson 
and Becker 1968, Harbison and Becker 1969). Finnell (1981) showed that 
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Fetal Hydantoin Syndrome is caused by the drug and not the disorder with 
an "epileptic" mouse model. Mice not treated with DPH that had regular 
convulsions during pregnancy gave rise to normal offspring. In humans, up 
to 30% of epileptic mothers on anticonvulsant medication give birth to 
babies with fetal hydantoin syndrome (Hanson 1986). The most common 
congenital malformations associated with the fetal hydantoin syndrome 
are: craniofacial anomalies, prenatal and postnatal growth deficiencies, 
mental retardation, and limb defects {Buehler et al. 1990, Hanson 1982}. 
Other anomalies that occur with less frequency include; microcephaly, 
ocular defects, cardiovascular anomalies, hypospadias, and umbilical and 
inguinal hernias (Buehler et al. 1990, Hanson 1986, Jones 1988). Although 
there is a risk of fetal malformation associated with the use of 
anticonvulsant drugs, the damage to the fetus from anoxia produced by a 
seizure could be greater {Lowe 1973, Monson et al. 1973}. 
Expression of Anomalies and the Teratogenicity of Phenytoin 
Expression of anomalies depends on the period during gestation when 
exposure to anticonvulsants occurs, dose, duration of exposure, and 
genetic predisposition {Wilson 1977, Finnell and Chernoff 1984}. Harbison 
and Becker (1969) showed that single administration of DPH to pregnant 
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Swiss-Webster mice on days 9-14 of gestation gave rise to various fetal 
anomalies, growth retardation, and sometimes death. Finnell (1991) 
suggested that structural defects could only be induced during limited 
"windows of sensitivity" which change over gestation for the different 
organ systems. 
Expression of anomalies is affected by the dosage of anticonvulsants 
taken (Witson 1977, Finnell and Chernoff 1984). In a study by Hill et al. 
(1974) mothers who used the combination of anticonvulsants, primidone 
and DPH, had the greatest number of life-threatening or disfiguring 
anomalies (three of six infants). In this same study, only two of nine 
infants treated with DPH alone had serious anomalies. lowe (1973) and 
Fedrick (1973) also observed that a combination of anticonvulsants 
increased the risk of producing a child with defects. Additionally, Fedrick 
(1973) noted a dosage response with phenobarbitone but not with 
phenytoin suggesting that the parent drug may not be the proximal 
teratogen. 
The duration of treatment before conception also may play a role in the 
expression of anomalies. Hill et al. (1974) observed that the infants most 
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- severely affected were born to mothers who had a history of seizures for 
an average of 21 years. 
Recently, more emphasis has been placed on the role of genetic 
predisposition for expression of anomalies. Individual fetuses with an 
enhanced sensitivity to a teratogen-induced pattern of malformation may 
have mutations in a specific biochemical pathway that alters the 
metabolism with a subsequent deleterious effect on embryonic 
development (Finnell 1 991). The teratogenicity of phenytoin is believed to 
be mediated by the toxic arene oxide intermediary metabolite, not by the 
parent compound (Buehler et al. 1 990, Blake and Martz 1980, Martz and 
Fallinger 1977, Wells and Harbison 1980). The biotransformation of 
phenytoin to its toxic oxidative metabolites is regulated by a cytochrome 
P450 enzyme system (Finnell 1992). Toxic arene oxide metabolites are 
highly reactive and can covalently bind to DNA, RNA, and protein to cause a 
disruption in normal development (Jerina and Daly 1974, Martz et al. 1977, 
Oesch 1976, Shanks et al. 1989, Spielberg et a!. 1981). Fetuses, when 
stressed in utero by phenytoin, do not readily metabolize the arene oxide 
metabolite making them substantially more susceptible to the teratogenic 
effects of this compound (Buehler et al. 1990). By measuring the epoxide 
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hydrolase activity with chromatographic assay in randomly selected 
amniocytes from 100 pregnant women, Buehler et a!. (1990) found a 
trimodal distribution of enzyme activity (Figure 1). This suggested three 
genotypes which is found in a one gene, two allele system. Buehler et al. 
(1990) found that amniocytes with low epoxide hydrolase activity 
(homozygous recessive) were the most susceptible to fetal hydantoin 
syndrome. Heterozygotes were better able to metabolize the drug and the 
homozygous dominants were at minimal risk for congenital 
malformations. 
Objectives of this Study 
This experiment wil1 attempt to show the effects of phenytoin on the 
fetus when injected preimplantation. Morphological differences, litter 
size, and percentage of no litter in DPH versus Control for the NSA Harlan 
strain and the AI J strain will be noted. Additionally, morphological 
differences will be noted for females versus males. 
Methods and Materials 
Mating the Mice 
Two females (NSA, Harlan Sprague Dawley, Indianapolis, IN or AI J, 
Jackson Lab, Bar Harbor, ME between the ages of 6.5-22 weeks) per one 
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Figure 1. Trimodal distribution of epoxide hydrolase 
activity in the normal population (Buehler 
et al. 1990). 
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male (B6SJLF1 / J, Jackson Lab, Bar Harbor, ME) were placed in a cage in 
the afternoon. They were allowed to mate overnight and in the morning 
the females were checked for sperm plugs. Plug positive females were 
separated from plug negative females. Half of the plug positive females 
were used as controls and half as experimentals. 
Injections 
The controls were injected intraperitoneally with .01 N NaOH. The 
experimentals were injected with 50 mg/kg of phenytoin dissolved in .01 
N NaOH. Injections were given for five days beginning on the day they 
were found to be plug positive (day 0). Injections were given at the same 
time each day ± one hour. 
Dissection of Fetuses from Mother 
On Day 1 8 of gestation, the mice were anesthetized with chloroform 
and were sacrificed by cervical dislocation to prepare for fetal 
dissection. The abdomen was cleansed with 70% alcohol and the skin was 
cut away to expose the viscera. The uterine horns were externalized and 
examined. The mother's ovaries were checked for the number of corpora 
lutea and the uterine horns were checked for implantation sites and for 
any resorptions. The number of fetuses per side of the uterus and total 
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number of fetuses was noted for each mouse. The fetuses were removed 
individually and placed in a dish with 0.9% sterile saline. 
Initial Analysis of Fetuses 
Fetuses were checked for any gross morphological defects and then 
were weighed in grams. Crown to rump length was measured in 
millimeters. Litters were stored together in Carnoy's fixative for at least 
a week before proceeding to the next step. 
External Morphological Analysis 
Before dissection of the fetus, several external features were noted. 
Right arm and right leg lengths were measured with a metric ruler from 
insertion into the body to the proximal end of the phalanges. The fourth 
phalange distally on the right front and right hind leg was measured to the 
nearest O.S mm. The distance between the eyes across the bridge of the 
nose was measured along with the crown to rump length. Also, the mouth 
was checked for cleft lip. 
Dissection of the Fetus 
1. Head 
The first cut on the fetus was made with a scalpel that separated the 
upper and lower jaws and slanted slightly to the neck. The tongue was 
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then removed and the palate was examined for a cleft. Then, one 
millimeter transverse sections were made through the head beginning at 
the nasal region. The first transverse section revealed bilateral nasal 
cavities that were checked for the normal open, vertical and uniform 
shape (the vomer being perpendicular to the palate). Another cut was 
made that passed through both eyes. Eyeballs were checked for uniformity 
and round shape. Another section was made between the frontal and 
parietal bones that revealed the lateral and third ventricles. The 
ventricles were checked for abnormal enlargement (internal 
hydrocephalus) or shrinkage (external hydrocephalus). The final cut was 
made to expose the cerebellum which was examined for gross 
morphological defects. Some other cuts were made that fell between 
these important sections in order to maintain the one millimeter 
thickness of the sections. 
2.~ 
Beginning in the neck region, the first transverse section was made to 
skip most of the glandular area. The next section was made to go through 
the heart. The interventricular septum was checked with a dissecting 
microscope for defects and the direction of the aortic arch was checked. 
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- The lungs, liver, stomach, pancreas, kidneys, intestines, and bladder were 
all checked for gross morphological defects. The reproductive system was 
examined and the sex was determined. 
Skeletal Analysis 
Fetuses from each litter were used for this analysis after being fixed. 
They were eviscerated and skinned and were placed in a series of 
solutions to disintegrate visceral tissue and dye skeletal portions. The 
order is given here: 
1. 2% KOH (3.5 days) 
2. Stain* (7 days) 
3. 37°C incubator in stain (8 hours) 
4. 2% KOH/25% glycerol (2 days) 
5. 2% KOH/50% glycerol (2 days) 
6. 50% glycerol (2 days) 
7. 1 00% glycerol (storage) 
*The recipe for stain (Kimmell 1981) with a doubling of the Alcian blue 
and Alizarin red for this experiment is as follows: 
4 parts Alcian blue 0.14% in 70% ethanol, filtered (stains cartilage) 
2 parts Alizarin red 0.12% in 95% ethanol, filtered (stains bone) 
8 parts Glacial acetic acid 
50 parts Ethanol 
Results 
For the first NSA group, female mice (22 g) were mated at age 9.5 
weeks. Six mice were plug positive so three were used as experimental 
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-and three for control. The experimentals were injected with 75 mg/kg 
(0.1 ml) of DPH and all three died. The controls were injected with 0.1 ml 
of 0.01 N NaOH. The first control mouse yielded 13 fetuses, the second 
had 11 fetuses, and the third had zero fetuses and zero resorptions. This 
dose of DPH was toxic to adults therefore the dose was reduced to SO 
mg/kg. 
For the second NSA group, female mice (22 g) were mated at age 10.5 
weeks. Two mice were plug positive and both were used as experimentals. 
The experimentals were injected with SO mg/kg (0.06 ml) of DPH. The 
first mouse yielded five live fetuses and two resorptions. The second 
mouse had zero fetuses. 
For the first AI J group, female mice (16 g) were mated at age 6.5 
weeks. Six mice were plug positive so three were used as experimentals 
and three for controls. The experimentals were injected with 55 mg/kg 
(0.04 ml) of DPH. The first DPH mouse yielded three fetuses, the second 
and third both had zero fetuses and zero resorptions. The controls were 
injected with 0.04 ml of 0.01 N NaOH. The first and third mice had zero 
fetuses and zero resorptions. The second mouse had one fetus and one 
resorption. 
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For the second A/J group, female mice (16 g) were mated at age 7.5 
weeks. Eight mice were plug positive so four were used as experimentals 
and four for controls. The experimentals were injected with 55 mg/kg 
(0.04 ml) of DPH and three of them died. The fourth mouse yielded five 
fetuses. The controls were injected with 0.04 ml of 0.01 N NaOH. The 
first control mouse yielded eleven fetuses with one of them being a runt. 
The second control yielded zero fetuses and seven resorptions. The third 
mouse had eight fetuses and the fourth had twelve fetuses. 
For the third AI J group, female mice (16 g) were mated at age 1 5 
weeks. Two mice were plug positive and both were used as experimentals. 
They were injected with 55 mg/kg (0.04 ml) of DPH. The first mouse 
yielded ten fetuses, one of which was not fully formed and dead. The 
second mouse had zero fetuses and seven resorptions. 
For the fourth AI J group, female mice (1 6 g) were mated at age 22 
weeks. Two mice were plug positive and both were used as experimentals. 
They were injected with 55 mg/kg (0.04 ml) of DPH. The first mouse 
yielded zero fetuses as did the second but the second had three 
resorptions. Table 1 summarizes this data. 
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NSA Group 1 NSA Group 2 A/J Group 1 A/J Group 2 A/J Group 3 A/J Group 4 
wt. of mother 22 g 22 9 ! 16 9 16 g 16 9 116 g 
10.5 weeks i 6.5 weeks ~-mating age 9.5 weeks 7.5 weeks 15 weeks 22 weeks 
_tI: plug positive I ~ _____ 21 .. ~ ---·-~--·-4:-----·--··--~ 
DPH injection 75 mg/kg 50 mg/kg '55 mg/kg 55 mg/kg ! 55 mg/kg ! 55 mg/kg 
Control inject. 0.1 ml 0.04ml 0.04 ml 
. _------
0..-. 
# in DPH litters 5(2), 0 3,0,0 5 9(1),0(7) 0,0{3) 
# in Cont. litter 13, 11, 0 0,0,1(1) 11,0(7),8,12 
! 
Note DPH dose too 3 DPH mothers 
high. All 3 died. ! 
mothers died. 
Table 1. Summary of the mating and litter data. !i.~f'!1.!>_er~ in parentheses represent the number of 
r-' 
resorptions in that litter. DPH dosage was reduced because of matemal death and to account for 
the smaller size of the AI J strain. 
".--. 
weight (g) CR length (mm) eye dist. (mm) arm (mm) leg (mm) 
NSA DPH (n=5) 0.565 16.6 3.7 3.9 4.2 
NSA CONT. (n=24) 1.138 21.8 4.1 4.8 5.6 
! 
4.1 ~ --i------~--AI J DPH (n= 1 8) 0.864 19.8 4 4.3 
AI j CONT. (n=32) 0.969 20.8 4.2 4 4.8 
Table 2. Averages of morphological data. 
DPH exposure caused a decrease in both strains of weight, 
CR length, and eye distance. Additionally, in the NSA strain 
arm and leg lengths were reduced. 
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Morphological data (weight, crown to rump length, eye distance, arm 
length, leg length, finger length, toe length, and sex) were collected and 
the averages are shown in Table 2. Control vs. DPH in the NSA strain had 
significantly different results (p ~ .05) using an independent t-test. DPH 
treated fetuses showed significant growth retardation (Figure 2) relative 
to controls. Weight averages, CR length averages, and leg length averages 
showed highly significant differences (p=2.3 x 10 .. t2.; p=3.2 x 10-B; p=.0007, 
respectively) compared to controls. Eye distance and arm length were 
also significantly reduced (p=.014; p=.016, respectively). Control vs. DPH 
in the AI J strain showed less of an overall growth retardation and only a 
slightly significant difference in CR length (p=.050) relative to AI J 
Controls. 
There were reductions in the litter size of the DPH treated animals in 
both strains (Table 3). NSA Control had an average litter size of 12 and 
NSA DPH had an average of 5. AI J Control had an average litter size of 8 
and AI J DPH had an average of 6. There was not a significant difference in 
the litter size of AI J compared to NSA. A comparison between strains and 
between females and males of DPH vs. Control yielded no significant 
differences. 
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Figure 2. Overall growth retardation 
in the NSA DPH (left) as compared to 
the NSA Control (right). 
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CONTROL litter size !DPH litter size 
NSA #1 13 
--.J. NSA #1 5 ._---
NSA #2 11 , I 
average 12 average 5 1--. _. 
--f----.. ---- -_ .. __ ... _--
A/J#H 11 A/J #1 3 
A/J #2 1 A/J #2 5 
A/J #3 12 A/J #3 (10) 
A/J#4 8 
average 8 average (6) 4 
, ! ! 
Table 3. Litter size and average litter size of DPH v~. Control. 
The average in parentheses is if A/ J #3 is included in the calculation. 
% no litter % resorptions 
NSA Control 33% (1/3) 0% (0/24) 
NSA DPH 50% (1/2) 28% (2/7) 
I 
AlJ Control 42% (317) - --~. --20% (8/40) 
A/J DPH 62.5% (5/8) 38% (11129) 
Table 4. Percent no litter and percent of resorptions. 
Both strains show an increase in % no litter and 
% resorptions with exposure to DPH. 
- IS 
- Percentages of no litters and number of resorptions are shown in Table 
4. DPH in both strains showed a higher percentage of no litter and a higher 
number of resorptions. NSA had 33% no litter and 0% resorptions in the 
control group. NSA with DPH treatment increased the percentages to 50% 
no litter and 28% resorptions. The AI J Control had 42% no litter and 20% 
resorptions. The AI J DPH increased to 62.5% no litter and 38% 
resorptions. 
Sectioning of the fetuses revealed no internal anomalies. It did, 
however, reinforce the previous measurements showing overall growth 
retardation by the reduced size of internal features (Figures 3 and 4). 
Discussion 
Most research on the effects of DPH focuses on the postimplantation 
stages of development when the embryo undergoes rapid growth. This 
experiment deals with the effects of DPH during preimplantation. 
Preimplantation in the mouse has seven stages: 1-cell, 2-cell, 4-cell, 
morula, early blastocyst, and late blastocyst. Implantation is the 
embedding of the developing blastocyst into the uterine mucosa and it 
occurs 4.5 days after fertilization (Taylor 1986). Because the 
19 
--
Figure 3. Transverse sections of an NSA DPH. 
Figure 4. Transverse sections of an NSA Control. Important aspects of the 
sections in Figures 3 and 4 can be found using this diagram: 
1'3 12. 1/ 1-2 nasal cavities, vomer, palate 
Stf.32"O 3 eyes 
'1 4-5 lateral and 3rd ventricles 
7 B 6 cerebellum 
8-9 interventricular septum, aortic arch,lungs 
10-11 liver, stomach, pancreas, kidney 
12-13 intestines, bladder, reproductive system 
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-blastomeres of the developing embryo are equipotent up to the early 8-
cell stage, it has been postulated that the effects of DPH during 
preimplantation are "all-or-none". This theory is not well supported in 
this case because of the wide range of expression of anomalies associated 
with the use of DPH. 
Differences in strains of mice also contributes to the range of 
anomalies expressed. In this experiment, two strains of female mice 
were used, AI J and NSA. The AI J strain is an inbred strain that is prone 
to phenytoin-induced cleft palate anomalies (Finnell 1991). The NSA 
strain is a randomly bred strain with varying sensitivities. The NSA 
strain in this experiment was very sensitive and had a large response to 
the treatment. The AI J strain did not show any cleft palate anomalies 
and, in general, did not respond as well to treatment as the NSA strain. 
The NSA morphological differences between Control and DPH were 
highly significant. The weight, CR length, eye distance, arm and leg 
lengths were all substanstially smaller in the DPH treated group. No other 
anomalies were noted. Finger and toe lengths were measured but because 
of their small size relative to the measuring instrument, no significant 
difference was noted. 
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-The AI J morphological differences between Control and DPH were not 
as pronounced. CR length was the only measurement that was significant 
and its significance was only slight. One AI J litter was abnormally large 
in size compared to the others. If this data is omitted, there is a 
significant difference in leg length. The unusually large size may be 
attributed to the mother's ability to metabolize the drug. If this is true 
then the mother may have been a heterozygote for arene oxide 
metabolizing activity allowing less of the drug to cross the placenta to 
affect the development of the fetuses. 
Epileptic women have an increased rate of spontaneous abortions 
(Nakane et al. 1980) that is amplified by the use of anticonvulsant drugs. 
The mice in this experiment showed early and late disruption of 
development as shown by the percent no litter and the number of 
resorptions. The DPH group in both strains showed a greater amount of no 
litter and resorptions than did the Control group. The significant 
difference in litter size is a reflection of these disruptions in 
development of the fetuses. The difference between strains was not 
significant. 
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Skeletal analysis of the Control group showed normal development but 
due to time constraints no examination of the DPH group was made. Other 
studies using postimplantation dosing have found skeletal anomalies such 
as inhibition of skeletal growth, lack of fusion of sternabrae, and fused 
vertebrae (Harbison and Becker 1969, Dabee et al. 1975). 
From this study, it has been shown that diphenylhydantoin does have 
an effect on the fetus when injected during preimplantation. Effects 
shown are the inability to establish pregnancy, increases in resorptions, 
small litter sizes, and overall growth retardation. These findings are 
supported by observations in other studies and, in humans, reinforces the 
need for epileptic women on anticonvulsants to consult a doctor in 
preparation for pregnancy. 
23 
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